Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs). METHODS: This analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90 days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression. RESULTS: 252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11 200 patients receiving TNFi (median follow-up per person 3.5 years and 5.3 years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups. CONCLUSIONS: Patients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“treatment with TNF inhibitors in rheumatoid arthritis, an overt inflammatory disease, is associated with a decreased risk of cardiovascular events”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009) · BMJ · doi:10.1136/bmj.b2393 · Cited by 7,299
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,736
Thygesen, K. A. (2007) · Circulation · Cited by 3,126
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Aviña‐Zubieta, J. A., Choi, H. K., Sadatsafavi, M., Etminan, M., Esdaile, J. M., & Lacaille, D. (2008) · Arthritis Care & Research · doi:10.1002/art.24092 · Cited by 1,462
Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J., & Lacaille, D. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200726 · Cited by 945
Maradit‐Kremers, H., Crowson, C. S., Nicola, P. J., Ballman, K. V., Roger, V. L., Jacobsen, S. J., & Gabriel, S. E. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20853 · Cited by 927
Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., Siu, S., Kraft, J., Lynde, C., Pope, J., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206624 · Cited by 907
Cited by
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690
Diagnosis and Management of Rheumatoid Arthritis: A Review
Aletaha, D., & Smolen, J. S. (2018) · JAMA · doi:10.1001/jama.2018.13103 · Cited by 2,313
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N. J., & Xu, J. (2018) · Bone Research · doi:10.1038/s41413-018-0016-9 · Cited by 1,767
“Compared with patients with RA receiving sDMARD therapy, TNFi can decrease the risk of myocardial infarction.(109) In the last 15 years, knowledge on the efficacy and toxicity of the TNFi has been published and was mainly gathered through regional or national registries created after these drugs reach the market.”
BackgroundIncreased cardiovascular risk in rheumatoid arthritis: mechanisms and implications
England, B. R., Thiele, G. M., Anderson, D. R., & Mikuls, T. R. (2018) · BMJ · doi:10.1136/bmj.k1036 · Cited by 609
Management of psoriasis as a systemic disease: what is the evidence?
Korman, N. J. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18245 · Cited by 539
Metadata
- Authors
- Low, A. S. L., Symmons, D. P. M., Lunt, M., Mercer, L. K., Gale, C. P., Watson, K. D., Dixon, W. G., & Hyrich, K. L.
- Affiliations
- University of Manchester (GB)
- Manchester Academic Health Science Centre (GB)
- University of Leeds (GB)
- Corresponding author
- Hyrich, Kimme L
- ORCID
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 76
- Issue
- 4
- Pages
- 654-660
- ISSN
- 0003-4967 (ISSN-L)
- PMC
- PMC5530342
- OpenAlex
- W2568758989
- Cited by
- 158
- References
- 36
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 12 · 2023: 21 · 2022: 14 · 2021: 17 · 2020: 20 · 2019: 30 · 2018: 21 · 2017: 9
- FWCI
- 19.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Annals of the Rheumatic Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- HighWire Press Open Archive (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Medical Research Council (G0701380/1, G0902272)
- Arthritis Research UK (20380)
- National Institute for Health Research (NIHR-CTF-2014-03-03)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Keywords
- rheumatoid arthritis, tumor necrosis factor inhibitors, myocardial infarction, cardiovascular risk, etanercept, infliximab, adalimumab, atherosclerosis, disease control
- MeSH terms
- Etanercept, Adalimumab, Infliximab, Adult, Aged, Arthritis, Rheumatoid, Female, United Kingdom, Humans, Male, Middle Aged, Myocardial Infarction, Severity of Illness Index, Tumor Necrosis Factor-alpha, Incidence, Antirheumatic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1136/annrheumdis-2016-209784
- The paper
- Low, A. S. L., Symmons, D. P. M., Lunt, M., Mercer, L. K., Gale, C. P., Watson, K. D., Dixon, W. G., & Hyrich, K. L. (2017). Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2016-209784
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.